Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions.

Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Stellmann JP, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Krumbholz M, Zeltner L, Ziemann U, Linker R, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl UK, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C; NEMOS (Neuromyelitis Optica Study Group).

Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e504. doi: 10.1212/NXI.0000000000000504. eCollection 2018 Nov.

2.

[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

Nervenarzt. 2018 Dec;89(12):1388-1399. doi: 10.1007/s00115-018-0607-0. Review. German.

PMID:
30264269
3.

Flaccid paralysis in neuromyelitis optica: An atypical presentation with possible involvement of the peripheral nervous system.

Grüter T, Ayzenberg I, Gahlen A, Kneiphof J, Gold R, Kleiter I.

Mult Scler Relat Disord. 2018 Oct;25:83-86. doi: 10.1016/j.msard.2018.07.032. Epub 2018 Jul 20.

PMID:
30056360
4.

Mobile Palliative Care Consultation Service (PCCS): Overview of Hospice and Palliative Care Evaluation (HOPE) Data on In-Patients With End-Stage Cancer, Multiple Sclerosis, and Noncancer, Nonneurological Disease From 4 PCCS Centers in Germany in 2013.

Basedow-Rajwich B, Montag T, Duckert A, Schulz C, Rajwich G, Kleiter I, Koehler J, Lindena G.

Palliat Care. 2018 Jul 18;11:1178224218785139. doi: 10.1177/1178224218785139. eCollection 2018.

5.

Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis.

Köpke S, Giordano A, Veronese S, Christin Rahn A, Kleiter I, Basedow-Rajwich B, Fornari A, Battaglia MA, Drulovic J, Kooij L, Koops J, Mens J, Meza Murillo ER, Milanov I, Milo R, Patti F, Pekmezovic T, Sastre-Garriga J, Vosburgh J, Voltz R, Bay J, Oliver DJ, Solari A.

Eur J Neurol. 2019 Jan;26(1):41-50. doi: 10.1111/ene.13760. Epub 2018 Sep 9.

PMID:
30035845
6.

Ovarian Reserve in Women With Neuromyelitis Optica Spectrum Disorder.

Thöne J, Lichtenberg S, Stahl A, Pache F, Kleiter I, Ruprecht K, Gold R, Hellwig K.

Front Neurol. 2018 Jun 19;9:446. doi: 10.3389/fneur.2018.00446. eCollection 2018.

7.

Laquinimod protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model.

Wilmes AT, Reinehr S, Kühn S, Pedreiturria X, Petrikowski L, Faissner S, Ayzenberg I, Stute G, Gold R, Dick HB, Kleiter I, Joachim SC.

J Neuroinflammation. 2018 Jun 14;15(1):183. doi: 10.1186/s12974-018-1208-3.

8.

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B.

J Neuroinflammation. 2018 May 3;15(1):134. doi: 10.1186/s12974-018-1144-2. Review.

9.

Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.

Huhn K, Bayas A, Doerck S, Frank B, Gerbershagen K, Hellwig K, Kallmann B, Kleinschnitz C, Kleiter I, Lee DH, Limmroth V, Mäurer M, Meuth S, Rieckmann P, Ruck T, Gold R, Linker RA.

J Neurol. 2018 Jul;265(7):1521-1527. doi: 10.1007/s00415-018-8871-2. Epub 2018 Apr 25.

PMID:
29696498
10.

MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.

Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, Trebst C, Pawlitzki M, Abdelhak A, Grüter T, Leypoldt F, Haas J, Kleiter I, Tumani H, Fechner K, Reindl M, Paul F, Wildemann B.

J Neuroinflammation. 2018 Mar 19;15(1):88. doi: 10.1186/s12974-018-1108-6.

11.

Nurse-led immunotreatment DEcision Coaching In people with Multiple Sclerosis (DECIMS) - Feasibility testing, pilot randomised controlled trial and mixed methods process evaluation.

Rahn AC, Köpke S, Backhus I, Kasper J, Anger K, Untiedt B, Alegiani A, Kleiter I, Mühlhauser I, Heesen C.

Int J Nurs Stud. 2018 Feb;78:26-36. doi: 10.1016/j.ijnurstu.2017.08.011. Epub 2017 Aug 26.

PMID:
28982479
12.

Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.

Kleiter I, Lang M, Jeske J, Norenberg C, Stollfuß B, Schürks M.

BMC Neurol. 2017 Sep 6;17(1):174. doi: 10.1186/s12883-017-0953-8.

13.

Numeracy of multiple sclerosis patients: A comparison of patients from the PERCEPT study to a German probabilistic sample.

Gaissmaier W, Giese H, Galesic M, Garcia-Retamero R, Kasper J, Kleiter I, Meuth SG, Köpke S, Heesen C.

Patient Educ Couns. 2018 Jan;101(1):74-78. doi: 10.1016/j.pec.2017.07.018. Epub 2017 Jul 17.

PMID:
28764895
14.

[Early onset of fingolimod-associated macular edema].

Schelenz D, Kleiter I, Schöllhammer J, Rehrmann J, Elling M, Dick HB, Kakkassery V.

Ophthalmologe. 2018 May;115(5):424-428. doi: 10.1007/s00347-017-0526-7. German.

PMID:
28653209
15.

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS.

Gahlen A, Trampe AK, Haupeltshofer S, Ringelstein M, Aktas O, Berthele A, Wildemann B, Gold R, Jarius S, Kleiter I.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e363. doi: 10.1212/NXI.0000000000000363. eCollection 2017 Jul.

16.

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.

Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, Fischer K, Hellwig K, Pache F, Ruprecht K, Havla J, Kümpfel T, Aktas O, Hartung HP, Ringelstein M, Geis C, Kleinschnitz C, Berthele A, Hemmer B, Angstwurm K, Young KL, Schuster S, Stangel M, Lauda F, Tumani H, Mayer C, Zeltner L, Ziemann U, Linker RA, Schwab M, Marziniak M, Then Bergh F, Hofstadt-van Oy U, Neuhaus O, Zettl U, Faiss J, Wildemann B, Paul F, Jarius S, Trebst C, Kleiter I; NEMOS (Neuromyelitis Optica Study Group).

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647. doi: 10.1136/jnnp-2017-315603. Epub 2017 Jun 1.

17.

Rho-associated protein kinase 2 (ROCK2): a new target of autoimmunity in paraneoplastic encephalitis.

Popkirov S, Ayzenberg I, Hahn S, Bauer J, Denno Y, Rieckhoff N, Radzimski C, Hans VH, Berg S, Roghmann F, Noldus J, Bien CG, Skodda S, Wellmer J, Stöcker W, Krogias C, Gold R, Schlegel U, Probst C, Komorowski L, Miske R, Kleiter I.

Acta Neuropathol Commun. 2017 May 29;5(1):40. doi: 10.1186/s40478-017-0447-3.

18.

Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.

Heesen C, Kleiter I, Meuth SG, Krämer J, Kasper J, Köpke S, Gaissmaier W.

J Neurol Sci. 2017 May 15;376:181-190. doi: 10.1016/j.jns.2017.03.001. Epub 2017 Mar 7.

PMID:
28431609
19.

Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?

Krämer J, Tenberge JG, Kleiter I, Gaissmaier W, Ruck T, Heesen C, Meuth SG.

PLoS One. 2017 Apr 13;12(4):e0174858. doi: 10.1371/journal.pone.0174858. eCollection 2017.

20.

SMAD7 deficiency stimulates Müller progenitor cell proliferation during the development of the mammalian retina.

Kugler M, Schlecht A, Fuchshofer R, Schmitt SI, Kleiter I, Aigner L, Tamm ER, Braunger BM.

Histochem Cell Biol. 2017 Jul;148(1):21-32. doi: 10.1007/s00418-017-1549-5. Epub 2017 Mar 3.

PMID:
28258388

Supplemental Content

Loading ...
Support Center